(Q38734141)

5 September 2017

title

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions (English)

1 reference

5 September 2017

1 reference

M B Atkins

1

1 reference

5 September 2017

J I Clark

series ordinal

2

1 reference

5 September 2017

D I Quinn

series ordinal

3

1 reference

5 September 2017

publication date

5 April 2017

1 reference

5 September 2017

1 reference

5 September 2017

volume

28

1 reference

5 September 2017

issue

7

1 reference

5 September 2017

page(s)

1484-1494

1 reference

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

21 January 2018

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Current and future systemic treatments for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Nivolumab: targeting PD-1 to bolster antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Development and validation of a scale to measure disease-related symptoms of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Pseudoprogression and Immune-Related Response in Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Emerging therapeutic approaches in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

PD-1 blockade in renal cell carcinoma: to equilibrium and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Checkpoint inhibitors in bladder and renal cancers: results and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX151

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDX151

1 reference

5 September 2017

1 reference